Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EKZ-102
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Financing
Eikonizo, Novo Nordisk Collaborate on EKZ-102 for Clinical Development
Details : The funding will be supporting the development of Eikonizo’s lead candidate, EKZ-102, a potential first-in-class, oral, CNS-penetrant, highly selective histone deacetylase 6 (HDAC6) inhibitor.
Product Name : EKZ-102
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : EKZ-102
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Financing